Avastin® development 
Add to favorites Print preview Recommend this page to a colleague

The hallmarks of cancer

  • Unlimited cell growth
  • Insensitivity to antigrowth signals
  • Reduced sensitivity to apoptosis
  • Functional immortality
  • Development and maintenance of vasculature (angiogenesis)
  • Invasion and metastasis

The balance hypothesis for the angiogenic switch

Development of Avastin® (bevacizumab)
Hanahan, et al. Cell 1996

Page   1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 
 
 
Privacy Policy | Legal Statement
The information on this Web site is intended only for visitors from Aruba, Bahamas, Barbados, Bermuda, Curacao, Jamaica, St. Maarten, St. Lucia and Trinidad & Tobago
All rights reserved © 2008 F. Hoffmann-La Roche Ltd.